Dashboard
Manage Tickers

AXSMAxsome Therapeutics, Inc.

Nasdaq axsome.com


$ 91.77 $ 0.72 (0.79 %)    

Thursday, 12-Sep-2024 15:59:34 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.99 $ 4.60 (0.98 %)
DIA $ 411.97 $ 2.70 (0.66 %)
SPY $ 558.49 $ 4.67 (0.84 %)
TLT $ 100.12 $ -0.47 (-0.47 %)
GLD $ 236.34 $ 4.08 (1.76 %)
$ 91.75
$ 90.47
-- x --
$ 91.94 x 100
$ 90.47 - $ 92.85
$ 55.02 - $ 98.40
274,964
na
4.4B
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 02-23-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-02-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-15-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-07-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-07-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-11-2016 03-31-2016 10-Q
35 03-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

what-analysts-are-saying-about-axsome-therapeutics-stock
What Analysts Are Saying About Axsome Ther...
09/09/2024 16:01:19

cantor-fitzgerald-reiterates-overweight-on-axsome-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:21:39

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...

cantor-fitzgerald-reiterates-overweight-on-axsome-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/06/2024 14:13:01

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...

hc-wainwright--co-reiterates-buy-on-axsome-therapeutics-maintains-180-price-target
HC Wainwright & Co. Reiterates Buy on Axso...
09/05/2024 11:49:01

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $18...

needham-reiterates-buy-on-axsome-therapeutics-maintains-130-price-target
Needham Reiterates Buy on Axsome Therapeut...
09/05/2024 10:12:45

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.

axsome-therapeutics-says-fda-has-acknowledged-resubmission-of-new-drug-application-for-axs-07-for-acute-treatment-of-migraine
Axsome Therapeutics Says FDA Has Acknowled...
09/04/2024 11:04:27

The FDA designated the resubmission as a Class 2 resubmission and set a Prescription Drug User Fee Act (PDUFA) action goal date...

wells-fargo-initiates-coverage-on-axsome-therapeutics-with-overweight-rating-announces-price-target-of-140
Wells Fargo Initiates Coverage On Axsome T...
09/03/2024 12:51:15

Wells Fargo analyst Cerena Chen initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Overweight rating and announc...

unveiling-14-analyst-insights-on-axsome-therapeutics
Unveiling 14 Analyst Insights On Axsome Th...
08/22/2024 14:00:14

hc-wainwright--co-reiterates-buy-on-axsome-therapeutics-maintains-180-price-target
HC Wainwright & Co. Reiterates Buy on Axso...
08/22/2024 13:23:55

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $18...

axsome-therapeutics-reaches-agreement-with-sandoz-to-dismiss-sunosi-patent-litigation
Axsome Therapeutics Reaches Agreement With...
08/21/2024 11:01:44

ubs-maintains-buy-on-axsome-therapeutics-lowers-price-target-to-105
UBS Maintains Buy on Axsome Therapeutics, ...
08/06/2024 15:32:44

UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $107 to $105.

lithia-motors-to-rally-around-14-here-are-10-top-analyst-forecasts-for-tuesday
Lithia Motors To Rally Around 14%? Here Ar...
08/06/2024 14:06:32

rbc-capital-maintains-outperform-on-axsome-therapeutics-lowers-price-target-to-130
RBC Capital Maintains Outperform on Axsome...
08/06/2024 12:38:01

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price targe...

hc-wainwright--co-maintains-buy-on-axsome-therapeutics-lowers-price-target-to-180
HC Wainwright & Co. Maintains Buy on Axsom...
08/06/2024 11:08:22

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the pri...

b-of-a-securities-upgrades-axsome-therapeutics-to-buy-raises-price-target-to-106
B of A Securities Upgrades Axsome Therapeu...
08/06/2024 10:24:49

B of A Securities analyst Jason Gerberry upgrades Axsome Therapeutics (NASDAQ:AXSM) from Neutral to Buy and raises the price...

needham-reiterates-buy-on-axsome-therapeutics-maintains-130-price-target
Needham Reiterates Buy on Axsome Therapeut...
08/06/2024 10:06:29

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.

a-glimpse-into-the-expert-outlook-on-axsome-therapeutics-through-9-analysts
A Glimpse Into The Expert Outlook On Axsom...
08/05/2024 17:00:39

needham-reiterates-buy-on-axsome-therapeutics-maintains-130-price-target
Needham Reiterates Buy on Axsome Therapeut...
08/05/2024 16:57:56

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.

axsome-therapeutics-q2-2024-adj-eps-112-beats-134-estimate
Axsome Therapeutics Q2 2024 Adj. EPS $(1.1...
08/05/2024 11:12:25

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $...

axsome-therapeutics-says-current-cash-is-sufficient-to-fund-anticipated-operations-into-cash-flow-positivity-based-on-current-operating-plan
Axsome Therapeutics Says Current Cash Is S...
08/05/2024 11:03:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION